EPFL researchers have achieved a remarkable result: capturing and studying phase changes in quantum hardware, which hold hold promise for next-generation technologies like quantum computing and ultra-sensitive sensors.

Research engineers at Saarland University and medical researchers at the Saarland University Medical Center are developing smart implants that can both monitor and promote healing in fractured bones. When installed at the fracture site, these implants, which are constructed using shape memory alloys, can stiffen or relax in a continuously controlled manner that optimizes bone healing. As part of an EU-funded project, the researchers are miniaturizing the technology for use in thin intramedullary nails (IMNs), which provide internal support and stability during the healing process. The team will be demonstrating this medical technology at Hannover Messe from 31 March to 4 April. Hall 2, Saarland Stand B10.

In the field of wireless communication, security is of utmost importance. A new study published in Engineering explores intelligent covert communication. It reviews current techniques across different domains, from time and frequency to spatial and modulation. The research also looks at future trends like intelligent cooperative and parasitic covert communication, as well as challenges such as dealing with active detection and integrating sensing and communication. This offers valuable insights for the development of more secure wireless communication methods.

A recent review has shed light on the transformative potential of acoustic technologies in the fields of biofabrication and tissue engineering.

Quaise Energy reports new insights into designing superhot geothermal plants in two recent papers. The geothermal plants of today work at relatively low temperatures, most ranging from about 100 to 250^oC. Less is known about designing plants for tapping into the heat in superhot rock over 375^oC, which could offer significant benefits. Daniel Dichter of Quaise is working to understand more, and presented his most recent results at two recent conferences.

 

A new study in the peer-reviewed journal Human Gene Therapy showed that more than half of individuals with Niemann-Pick disease, type C1 (NPC1) who were tested lacked neutralizing antibodies against either adeno-associated virus (AAV) 2 or AAV9.